© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Expert panelists center discussion on patient cases to highlight optimal management strategies in patients with hepatocellular carcinoma.
June 24th 2022
Sharing the first patient case of unresectable hepatocellular carcinoma, experts consider optimal screening and diagnosis practices in this setting.
Expert perspectives on the role of transarterial radioembolization in unresectable hepatocellular carcinoma following FDA approval.
July 1st 2022
A brief discussion on the role of systemic therapies in combination with or following TACE/TARE in unresectable hepatocellular carcinoma.
Shifting to a second patient case of metastatic hepatocellular carcinoma, experts consider best diagnostic practices and the initiation of therapy.
July 8th 2022
Panelists debate the role of imaging in conjunction with or in place of biopsy in the setting of metastatic hepatocellular carcinoma.
Focused discussion on the frontline treatment options available for patients diagnosed with metastatic hepatocellular carcinoma.
July 15th 2022
Shared insight on clinical trial data in metastatic hepatocellular carcinoma supporting frontline use of sorafenib and lenvatinib, respectively.
Comprehensive discussion on the PFS subgroup data from REFLECT, which compared frontline lenvatinib and sorafenib therapy in metastatic HCC.
July 22nd 2022
Panelists consider the adverse event profile of frontline TKI therapy in patients with metastatic HCC and review options for dosing and dose reduction.
A brief review of treatment options for patients with Child-Pugh B grade metastatic hepatocellular carcinoma.